Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Revving Newron's engine

Newron SpA has developed its ion channel discovery platform to the point where it is beginning to monetize its investment in areas outside of its core CNS focus. A case in point is its recent licensing

Read the full 367 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers